

# **EHang Holdings Limited**

**Q2 2021 Earnings Highlights** 



### **Disclaimer**

These materials have been prepared by EHang Holdings Limited (the "Company") solely for informational purposes, and have not been independently verified. No representations or warranties, express or implied, are made as to, and no reliance should be placed on, the accuracy, fairness, completeness or correctness of the information or opinions presented or contained in these materials. None of the Company, its subsidiaries, affiliates, controlling persons, directors, supervisors, officers, partners, employees, advisors, and representatives of any of the foregoing shall have any responsibility or liability whatsoever, as a result of negligence or otherwise, for any loss howsoever arising from any information or opinions presented or contained in or derived from these materials. The information and opinions presented or contained in these materials is subject to change without notice, and shall only be considered current as of the date of the presentation.

This presentation includes forward-looking statements, which are based on current expectations and forecast about future events. These statements can be recognized by the use of words such as "expect," "plan," "will," "estimate," "project," "intend," or words of similar meaning. These forward-looking statements are made only, and are based on estimates and information available to the Company, as of the date of this presentation, and are not guarantees of future performance. These statements are based on a number of assumptions which are subject to known and unknown risks, uncertainties and other factors that are beyond the Company's control, which could cause actual results to differ materially from historical results or those anticipated. These factors include, but are not limited to, the political, social, legal and economic environment in which the Company will operate in the future. The Company and its affiliates and representatives undertake no obligation to update or revise these forward-looking statements for events or circumstances that occur subsequent to the date of this presentation. Actual results could differ materially from those anticipated in forward-looking statements and future results could materially differ from our historical performance.

This presentation is not and does not constitute or form part of, and is not made in connection with, any offer, invitation or recommendation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of any entity, and neither this presentation nor anything contained in it shall form the basis of, or be relied upon in connection with, any contract or investment decision.

Certain data in this presentation was obtained from various external data sources, and the Company has not verified such data with independent sources. Accordingly, the Company makes no representations as to the accuracy or completeness of that data, and such data involves risks and uncertainties and is subject to change based on various factors. The figures in this document may have been subject to rounding.

This presentation speaks as of August 25, 2021. The information presented or contained in this presentation is subject to change without notice. Neither the delivery of this presentation nor any further discussions of the Company, any of its affiliates, shareholders, directors, employees, agents or advisors with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

By attending this presentation and viewing and accessing these materials, you agree to keep these materials strictly confidential and be bound by the limitations set forth herein. These materials are being given solely for your use and may not be retained, copied, reproduced, redistributed or otherwise disclosed, directly or indirectly to any other person in any manner, or published, in whole or in part, for any purpose. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

# **GHVNQ**

# **OPERATIONAL HIGHLIGHTS FOR Q2 2021**



# Release of Long-Range VT-30 Passenger-grade AAV to Expand Regional Air Mobility Coverage

• In May, EHang released the "VT-30", a new model of electric dual-seat passenger-grade AAV in EHang's product suite that is designed for inter-city air transportation and complementary to the EHang 216 designed for intra-city air mobility. With a hybrid structure of eVTOL and fixed wings, the VT-30 is designed to travel a distance of up to 300km with a designed flight time of up to 100 minutes.



## **EH216 AAV's CAAC Type Certification Process Prioritized**

- In January this year, the Civil Aviation Administration of China ("CAAC") officially accepted EHang's Type Certification application for the EHang 216 AAV.
- Since April, the CAAC's designated type certification expert team has conducted several rounds of review meetings and inspections. Critical consensus has been reached that the type certification of EHang 216 AAV is an important project in China and needs to be prioritized.



### Continued Trial Flights to Further Demonstrate AAV Technical Strength and UAM Use Cases

- As the first mover and industry leader with strong capabilities of autonomous flying, EHang with local partners continued trial and demo flights with the EHang 216 AAV series at multiple public events showcasing its practical uses.
- For example, its maiden flight in Japan was successfully completed with the local partner in June with Japan's first outdoor open airspace trial flight permission granted to a passenger-grade AAV.
- In April, the EHang 216 made an impressive debut at the Chinese Super League in Guangzhou by flying into the opening ceremony carrying a representative holding the championship trophy.
- In June, EHang participated in the anti-COVID-19 campaign in Guangzhou by transporting emergency supplies to quarantine areas using the EHang 216 and the EHang 216L AAVs.











## Completion of EH216F's Technical Examination and Urban Fire Rescue Drills in China

In July, EHang completed a comprehensive 10-month technical examination on the EHang 216F and 52 different types of tests by the China National Fire-Fighting Equipment Quality Supervision Testing Center, which is under the Ministry of Emergency Management of China.

In August following the examination, the EHang 216F AAVs were utilized by the local emergency and/or fire departments in several urban fire rescue drills in China's cities of Qingdao, Guangzhou and Hezhou. These have laid a solid foundation for the commercialization of the EHang 216F AAVs.

Hezhou, China





# **Commencement of Operations in Yunfu Production Facility**

• EHang's new production facility in Yunfu, China commenced operations in June. It is approximately 24,000 square meters in gross floor area to house the major AAV production processes from manufacturing key components and carbon fiber composite airframes to AAV assembling and flight testing in designated function areas. It has a planned initial annual capacity of 600 units of passenger-grade AAVs.











# **100 Air Mobility Routes Initiative**

### **Objective:**

To implement 100 air mobility routes in 2 years with an initial focus on the Guangdong-Hong Kong-Macao Greater Bay Area of China.

### **Progress:**

- Expanded a professional air mobility operation team
- Targeted 15 self-run operation spots and 21 customer-run operation spots
- Screened and tested 7 operation spots



# **GHVNQ**





# **Q2 2021 Financial Highlights**

### Achieved Record High Quarterly Gross Margin Again


| (RMB '000)                     | Q2 2021  | Q2 2020  | YoY                  |
|--------------------------------|----------|----------|----------------------|
| Total revenues                 | 12,164   | 35,700   | -65.9%               |
| Gross profit                   | 8,267    | 20,553   | -59.8%               |
| Gross margin                   | 68.0%    | 57.6%    | 10.4Pp <sup>2)</sup> |
| Adjusted gross profit 1)       | 8,267    | 20,553   | -59.8%               |
| Adjusted gross margin 1)       | 68.0%    | 57.6%    | 10.4Pp <sup>2)</sup> |
| Adjusted operating expenses 1) | (59,851) | (35,424) | 69.0%                |
| Adjusted operating loss 1)     | (49,421) | (11,147) | 343.4%               |
| Adjusted net loss 1)           | (49,104) | (11,716) | 319.1%               |

#### Notes


<sup>1)</sup> The Company uses Non-GAAP Financial Measures in evaluating its operating results and for financial and operational decision-making purpose. Please refer to the press release for more details.

<sup>2)</sup> Pp represents percentage points.

### **Q2 2021 Financial Performance**








### **Q2 2021 Financial Performance**


### (Adjusted) OPEX

#### RMB '000




### (Adjusted) Operating Loss

#### RMB '000



### (Adjusted) Net Loss

#### **RMB** '000



# **Unaudited Condensed Consolidated Balance Sheets**

| (RMB '000)  | As of December 31, 2020 | As of June 30, 2021 |  |
|---|-------------------------|---------------------|--|
| Current assets:                                   |                         |                     |  |
| Cash and cash equivalents                         | 137,840                 | 319,919             |  |
| Restricted cash                                   | 2,333                   | -                   |  |
| Short-term investments                            | 49,271                  | 86,561              |  |
| Accounts receivable                               | 163,146                 | 111,079             |  |
| Cost and estimated earnings in excess of billings | 717                     | 717                 |  |
| Inventories, net                                  | 47,094                  | 54,197              |  |
| Prepayments and other current assets              | 21,421                  | 31,257              |  |
| Others, net                                       | 2,639                   | 2,639               |  |
| Total current assets                              | 424,461                 | 606,369             |  |
| Non-current assets:                               |                         |                     |  |
| Property and equipment, net                       | 20,869                  | 34,610              |  |
| Long term loans receivable                        | 14,934                  | 13,162              |  |
| Long-term investments                             | 2,919                   | 2,919               |  |
| Others, net                                       | 21,366                  | 4,174               |  |
| Total non-current assets                          | 60,088                  | 54,865              |  |
| Total assets                                      | 484,549                 | 661,234             |  |
| Current liabilities:                              |                         |                     |  |
| Short-term bank loans                             | 15,000                  | 10,000              |  |
| Accounts payable                                  | 53,147                  | 35,770              |  |
| Contract liabilities                              | 7,492                   | 17,029              |  |
| Accrued expenses and other liabilities            | 81,578                  | 59,000              |  |
| Others, net                                       | 830                     | 2,466               |  |
| Total current liabilities                         | 158,047                 | 124,265             |  |
| Non-current liabilities:                          |                         |                     |  |
| Long-term bank loans                              | -                       | 20,000              |  |
| Mandatorily redeemable non-controlling interests  | 40,000                  | 40,000              |  |
| Others, net                                       | 8,802                   | 8,364               |  |
| Total non-current liabilities                     | 48,802                  | 68,364              |  |
| Total liabilities                                 | 206,849                 | 192,629             |  |
| Total shareholders' equity                        | 277,700                 | 468,605             |  |
| Total liabilities and shareholders' equity        | 484,549                 | 661,234             |  |
|   |                         |                     |  |


# **Unaudited Condensed Consolidated Statements of Comprehensive Loss**

| (RMB '000)   | 2020 Q2  | 2021 Q1  | 2021 Q2  | 2020 H1  | 2021 H1   |
|--|----------|----------|----------|----------|-----------|
| Total revenues   | 35,700   | 22,977   | 12,164   | 54,518   | 35,141    |
| Costs of revenues  | (15,147) | (8,451)  | (3,897)  | (22,811) | (12,348)  |
| Gross profit   | 20,553   | 14,526   | 8,267    | 31,707   | 22,793    |
| Operating expenses:  |          |          |          |          |           |
| Sales and marketing expenses   | (9,218)  | (9,486)  | (10,762) | (14,994) | (20,248)  |
| General and administrative expenses                                  | (16,348) | (46,059) | (42,809) | (26,956) | (88,868)  |
| Research and development expenses                                    | (17,870) | (27,854) | (31,769) | (34,530) | (59,623)  |
| Total operating expenses   | (43,436) | (83,399) | (85,340) | (76,480) | (168,739) |
| Other operating income   | 3,724    | 2,667    | 2,163    | 4,493    | 4,830     |
| Operating loss   | (19,159) | (66,206) | (74,910) | (40,280) | (141,116) |
| Other income/(expense):  |          |          |          |          |           |
| Interest and investment income                                       | 974      | 1,957    | 561      | 2,386    | 2,518     |
| Interest expenses  | (488)    | (394)    | (474)    | (976)    | (868)     |
| Foreign exchange gain/(loss)   | 278      | (306)    | 38       | 7        | (268)     |
| Other(expense)/income/   | (1,445)  | 2,541    | 192      | (1,364)  | 2,733     |
| Total other income/(expense)   | (681)    | 3,798    | 317      | 53       | 4,115     |
| Loss before income tax and share of net loss from an equity investee | (19,840) | (62,408) | (74,593) | (40,227) | (137,001) |
| Income tax benefits/(expenses)                                       | 145      | (117)    | -        | 145      | (117)     |
| Loss before share of net loss from an equity investee                | (19,695) | (62,525) | (74,593) | (40,082) | (137,118) |
| Share of net loss from an equity investee                            | (33)     | -        | -        | (52)     | -         |
| Net loss   | (19,728) | (62,525) | (74,593) | (40,134) | (137,118) |
| Net loss attributable to non-controlling interests                   | 1,111    | 361      | 197      | 1,967    | 558       |
| Net loss attributable to ordinary shareholders                       | (18,617) | (62,164) | (74,396) | (38,167) | (136,560) |
|  |          |          |          |          |           |

# **Unaudited Condensed Consolidated Statements of Cash Flows**

| (RMB '000)  | 2020 Q2      | 2021 Q1  | 2021 Q2   | 2020 H1  | 2021 H1   |
|---|--------------|----------|-----------|----------|-----------|
| CASH FLOWS FROM OPERATING ACTIVITIES  |              |          |           |          |           |
| Net loss  | (19,728)     | (62,525) | (74,593)  | (40,134) | (137,118) |
| Adjustments to reconcile net loss to net cash used in operating activities:                                   |              |          |           |          |           |
| Share-based compensation  | 8,012        | 48,871   | 25,489    | 9,948    | 74,360    |
| Allowance for doubtful accounts   | 3,727        | 505      | 5,869     | 3,869    | 6,374     |
| Others, net   | 1,881        | (410)    | 2,107     | 3,470    | 1,697     |
| Changes in operating assets and liabilities:  |              |          |           |          |           |
| Accounts receivable   | (30,900)     | 54,542   | (8,220)   | (39,991) | 46,322    |
| Cost and estimated earnings in excess of billings   | -            | -        | -         | 10,490   | -         |
| Inventories   | (18,868)     | 318      | (10,849)  | (30,021) | (10,531)  |
| Accounts payable  | 11,446       | (17,789) | 412       | 14,142   | (17,377)  |
| Contract liabilities  | (170)        | 1,613    | (1,476)   | (3,513)  | 137       |
| Accrued expenses and other liabilities  | (1,387)      | (3,534)  | 7,548     | (2,990)  | 4,014     |
| Others, net   | 1,238        | (5,417)  | (5,663)   | 926      | (11,080)  |
| Net cash (used in)/provided by operating activities   | (44,749)     | 16,174   | (59,376)  | (73,804) | (43,202)  |
| CASH FLOWS FROM INVESTING ACTIVITIES  | , ,          | •        | , , ,     | , ,      | ,         |
| Purchase of property and equipment  | (866)        | (8,322)  | (3,732)   | (1,158)  | (12,054)  |
| Proceeds from maturity of short-term investments  | 2,500        | 49,271   | 56,600    | 15,500   | 105,871   |
| Purchase of short-term investments  | (19,899)     | (18,000) | (125,161) | (37,099) | (143,161) |
| Loans to third parties  | -            | -        | -         | (53,900) | -         |
| Repayment of loan from a third party  | -            | -        | -         | 10,000   | -         |
| Others, net   | (77)         | (9)      | (11)      | (140)    | (20)      |
| Net cash (used in)/provided by investing activities   | (18,342)     | 22,940   | (72,304)  | (66,797) | (49,364)  |
| CASH FLOWS FROM FINANCING ACTIVITIES  | , ,          |          | • • •     | , , ,    |           |
| Proceeds from short-term bank loans   | 5,000        | 5,000    | -         | 10,000   | 5,000     |
| Repayment of short-term bank loans  | -            | (5,000)  | (5,000)   | (5,000)  | (10,000)  |
| Proceeds from long-term bank loans  | -            | 20,000   | -         | -        | 20,000    |
| Proceeds from issuance of mandatorily redeemable non-controlling interests of a subsidiary                    | 40,000       | -        | -         | 40,000   | -         |
| Proceeds from issuance of subsidiaries' equity to non-controlling interest holders                            | 2,023        | -        | -         | 2,023    | -         |
| Proceeds from issuance of Class A ordinary shares pursuant to underwriters' exercise of over-allotment option | <del>-</del> | -        | -         | 7,313    | -         |
| Proceeds from the issuance of Class A ordinary shares pursuant to a private placement                         | -            | 258,836  | -         | -        | 258,836   |
| Payment of issuance of Class A ordinary shares pursuant to underwriters' exercise of over-allotment option's  |              | ,        |           | (= ( 0 ) |           |
| issuance costs  | -            | -        | -         | (516)    | -         |
| Payment of issuance costs for initial public offering   | (304)        | -        | -         | (9,423)  | _         |
| Net cash (used in)/provided by financing activities   | 46,719       | 278,836  | (5,000)   | 44,397   | 273,836   |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash                              | (454)        | 4,351    | (5,875)   | 2,731    | (1,524)   |
| Net (decrease)/increase in cash and cash equivalents and restricted cash                                      | (16,826)     | 322,301  | (142,555) | (93,473) | 179,746   |
| Cash and cash equivalents and restricted cash at the beginning of the period/year                             | 245,015      | 140,173  | 462,474   | 321,662  | 140,173   |
| Cash and cash equivalents and restricted cash at the end of the period/year                                   | 228,189      | 462,474  | 319,919   | 228,189  | 319,919   |

### **Investment Highlights**



- World's First Publicly Traded Urban Air Mobility Company
- Massive, Fast-growing Target Market Ready for True Disruption
- Global Market Leader and First Mover of Commercialization Ahead of Competition
- World's Leading Scalable Urban Air Mobility Platform with Integrated Product Suite
- 5 Continuous, Industry-disruptive Regulatory Breakthroughs
- Compelling High Growth and Margin Business Model
- Ecosystem Enabler with Global Partnership Network
- Experienced, Entrepreneurial Management Team

CHANG IZ病

